Research reference
SEMA
Semaglutide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1), modified for a long half-life. It is supplied as a lyophilised powder for laboratory research applications only.
Molecular information
Type
GLP-1 receptor agonist
Length
31 amino acids
Formula
C187H291N45O59
Weight
4113.6 g/mol
CAS
910463-68-2
Form
Lyophilised powder
Vial sizes
10 mg / 20 mg
Classification
Incretin mimetic
Sequence
- 01His
- 02Aib
- 03Glu
- 04Gly
- 05Thr
- 06Phe
- 07Thr
- 08Ser
- 09Asp
- 10Val
- 11Ser
- 12Ser
- 13Tyr
- 14Leu
- 15Glu
- 16Gly
- 17Gln
- 18Ala
- 19Ala
- 20Lys(C18 diacid)
- 21Glu
- 22Phe
- 23Ile
- 24Ala
- 25Trp
- 26Leu
- 27Val
- 28Arg
- 29Gly
- 30Arg
- 31Gly
H[Aib]EGTFTSDVSSYLEGQAAKEFIAWLVRGRG
Research overview
Semaglutide is based on native GLP-1(7-37) with three main changes. An Aib residue at position 8 protects it from breakdown by DPP-4, lysine 34 is replaced with arginine, and a C18 fatty diacid chain on lysine 26 lets it bind albumin. Together these extend its half-life to around one week. Research models use it to study GLP-1 receptor signalling, glucose-dependent insulin secretion, gastric emptying and appetite regulation.
Common research focus areas
Laboratory research use only
This product is supplied strictly for laboratory research use. It is not a medicine, food, cosmetic, or dietary supplement, and is not for human or animal consumption. Any use outside a documented laboratory research protocol is prohibited.
Handling
For laboratory use, reconstitute with a sterile diluent appropriate to the research protocol, introducing the diluent slowly against the vial wall to minimise peptide degradation. Do not shake.
Published research
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue SemaglutideLau J et al. · Journal of Medicinal Chemistry · 2015 · DiscoveryPMID 26308095
- Once-Weekly Semaglutide in Adults with Overweight or ObesityWilding JPH et al. · New England Journal of Medicine · 2021 · Randomised controlled trialPMID 33567185
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesMarso SP et al. · New England Journal of Medicine · 2016 · Randomised controlled trialPMID 27633186
Evidence status
Semaglutide has been studied in large randomised controlled trials and is licensed as a prescription medicine under specific brand names. The material supplied here is a research-grade compound, is not a licensed medicine, and is intended for laboratory research only.
